Cortes J, Cescon DW, Rugo HS, Nowecki Z, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously
untreated locally recurrent inoperable or metastatic triple-negative breast
cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3
clinical trial. Lancet 2020;396:1817-1828.
PMID: 33278935